About this journal
Aims and scope
Stem Cells and Cloning: Advances and Applications is an international, peer-reviewed, Open Access journal that publishes: Original Research; Reviews; Hypothesis Formation; Commentaries; Technology Reviews and Short Reports.
Stem Cells and Cloning: Advances and Applications will no longer consider meta-analyses for publication.
Areas of interest in established and emerging concepts in stem cell research include, but are not limited to, the following:
- Embryonic cell stems
- Adult stem cells
- Blastocysts
- Cordblood stem cells
- Stem cell transformation and culture
- Therapeutic cloning
- Autologous embryonic cell lines
- Umbilical cord blood and bone marrow cells
- Laboratory, animal and human therapeutic studies
- Philosophical and ethical issues related to stem cell research.
Journal metrics
Usage
- 19K annual downloads/views
Citation metrics
- 1.7 (2023) Impact Factor
- 2.7 (2023) 5 year IF
- 6.5 (2023) CiteScore (Scopus)
- Q1 CiteScore Best Quartile
- 0.762 (2023) SNIP
- 0.689 (2023) SJR
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editor-in-Chief:
Dr Bernard Binetruy, Directeur de Recherche INSERM, Faculte de Medecine, Inserm, France
Editorial Board:
Prof. Dr. Zeev Blumenfeld, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
Dr Pankaj Chaturvedi, Cell and Developmental Biology, University of Illinois at Urbana-Champaign, United States
Professor Michael Griswold, School of Molecular Biosciences, College of Sciences, Washington State University, WA, United States
Professor Dan Liebermann, The Fels Institute for Cancer Research and Molecular biology; and Medical Genetics & Molecular Biochemistry, Temple University School of Medicine, Philadelphia, PA, United States
Professor Joseph Locker, Pathology, University of Pittsburgh School of Medicine, United States
Dr Andres Matoso, Pathology, Johns Hopkins University, United States
Professor Colin McGuckin, Cell Therapy Research Institute, Lyon, France
Dr Louis Pelus, Department of Microbiology and Immunology, Indiana University School of Medicine, United States
Dr John Rossi, School of Biological Sciences Molecular and Cellular Biology, Beckman Research Institute of City of Hope, United States
Dr Dario Siniscalco, Department of Experimental Medicine, University of Campania, Naples, Italy
Professor Kiminobu Sugaya, College of Medicine, University of Central Florida, FL, United States
Prof. Dr. Marco Tatullo, Applied Technical Medical Sciences University of Bari, Italy
Professor Cory Xian, SUniSA Clinical & Health Sciences, University of South Australia, Australia
Professor Martin Yarmush, Biomedical Engineering, Rutgers University, United States
Professor John Zaia, Centre for Gene Therapy, City of Hope, United States
Abstracting and indexing
Stem Cells and Cloning: Advances and Applications is indexed/tracked/covered by the following services:
Directory of Open Access Journals (DOAJ)
EMBASE (Elsevier)
Pubmed (NLM)
PubMed Central Selective Deposit Medicine & Health (NLM)
Scopus (Elsevier)
Open access
Stem Cells and Cloning: Advances and Applications is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
Continuous
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors